AL
JNCE

AJO LP’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

AJO LP’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,460
Closed -$82K – 842
2020
Q1 		$82K Buy
17,460
+4,168
+31% +$24K ﹤0.01% 611
2019
Q4 		$116K Buy
+13,292
New +$71.8K ﹤0.01% 536

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

AJO LP's JNCE Position: Q2 2020 in Review

AJO LP sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2020, closing a stake of 17,460 shares — an estimated $82K sold.

AJO LP first reported a position in JNCE in Q4 2019 and held it in 2 quarters. The position peaked at $116K in Q4 2019. 90 funds tracked by Wall St. Rank hold JNCE as of Q2 2020.

  • AJO LP reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • AJO LP sold 17,460 Jounce Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $82K.
  • AJO LP first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • AJO LP's Jounce Therapeutics, Inc. Common Stock position peaked at $116K in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2020.

Based on AJO LP's 13F filing for Q2 2020, filed 12 Aug 2020.